We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital CZT Detectors Developed for Pre-clinical Imaging

By Biotechdaily staff writers
Posted on 11 Oct 2007
New digital cadmium zinc telluride (CZT) detectors for nuclear imaging applications have advantages over photomultiplier tube- (PMT)-based detectors, including that of increased sensitivity.

Gamma Medica-Ideas, Inc. More...
(GM-I; Oslo, Norway), a developer of digital medical imaging devices for the pre-clinical and clinical markets, has recently developed digital cadmium zinc telluride (CZT) detectors for nuclear imaging. The Oklahoma Medical Research Foundation (OMRF; Oklahoma City, OK, USA) installed the detectors in a dual-modality single photon emission tomography/computed tomography (SPECT/CT) configuration for pre-clinical imaging.

Dr. Rheal Towner, director of the MRI (Magnetic Resonance Imaging) Facility for the Free Radical Biology & Aging Research Program at OMRF, reported that GM-I's digital CZT detectors offer strong advantages over photomultiplier tube (PMT)-based detectors. "Gamma Medica-Ideas' state-of-the-art digital CZT detectors allow OMRF to benefit from increased sensitivity, which traditional PMT-based detectors cannot provide,” said Dr. Towner.

Oklahoma Medical Research Foundation's main research efforts are grouped into three major areas: cancer research, neurologic disease research, and cardiovascular disease research. Gamma Medica-Ideas' Flex system currently installed in OMRF's Small Animal Imaging Facility is used principally to look at metastases in animal cancer models, study metastases in lungs and design molecular targeted agents.

"Digital detection systems for nuclear medicine will soon make analog photomultiplier tube-based systems obsolete in the same way that digital mobile phones replaced analog cellular and digital technology has taken over analog in every audio/video market. It's more efficient, more reliable, and vastly better technology. With digital technology everything is better--performance, maintenance, and upgrading,” said Gamma Medica-Ideas president and CEO, Dr. Bradley Patt.

Gamma Medica-Ideas' Flex pre-clinical system, recently upgraded to the Flex Triumph multi-modality pre-clinical platform, provides multiple configurations to meet user needs. It can combine up to three different imaging modalities (PET [positron emission tomography], SPECT, and CT) in a single platform. Major application areas include cardiology, neurology, oncology, and bone analysis.


Related Links:
Gamma Medica-Ideas
Oklahoma Medical Research Foundation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.